Luigi Gianturco

Dr. Luigi Gianturco

ASST RHODENSE
+1
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2010 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
PDF file
MTM. Turiel
M. Turiel
LTL. Tomasoni
L. Tomasoni
SSS. Sitia
S. Sitia
SCS. Cicala
S. Cicala
Luigi GianturcoLuigi Gianturco
Luigi Gianturco
Piercarlo Sarzi-PuttiniPiercarlo Sarzi-Puttini
Piercarlo Sarzi-Puttini
Rheumatoid arthritis (RA) is associated with enhanced atherosclerosis and impaired endothelial function early after the onset of the disease and cardiovascular (CV) disease represents one of the leading causes of morbidity and mortality. It is well known that disease modifying antirheumatic drugs (DMARDs) are able to improve the course of the disease and the quality of life of these patients, but little is known about the effects of DMARDs on CV risk and endothelial dysfunction. Our goal was to examine the effects of long‐term therapy with DMARDs on endothelial function and disease activity in early RA (ERA). Twenty‐five ERA patients (mean age 52 ± 14.6 years, disease duration 6.24 ± 4.10 months) without evidence of CV involvement were evaluated for disease activity score (DAS‐28), 2D‐echo derived coronary flow reserve (CFR), common carotid intima‐media thickness (IMT) and plasma asymmetric dimethylarginine (ADMA) levels at baseline and after 18 months of treatment with DMARDs (10 patients with methotrexate and 10 with adalimumab). DMARDs significantly reduced DAS‐28 (6.0 ± 0.8 vs. 2.0 ± 0.7; P < 0.0001) and improved CFR (2.4 ± 0.2 vs. 2.7 ± 0.5; P < 0.01). Common carotid IMT and plasma ADMA levels did not show significant changes. The present study shows that DMARDs, beyond the well known antiphlogistic effects, are able to improve coronary microcirculation without a direct effect on IMT and ADMA, clinical markers of atherosclerosis. Treatment strategies in ERA patients with high inflammatory activity must be monitored to identify beneficial effects on preclinical markers of vascular function.

28 April 2015 in Immunotherapy
Verified
Journal Article
Closed access
FAFabiola Atzeni
Fabiola Atzeni
Luigi GianturcoLuigi Gianturco
Luigi Gianturco
RTRossella Talotta
Rossella Talotta
VVValentina Varisco
Valentina Varisco
MDMaria Chiara Ditto
Maria Chiara Ditto
Piercarlo Sarzi-PuttiniPiercarlo Sarzi-Puttini
Piercarlo Sarzi-Puttini
There are now five anti-TNF drugs available for clinical use, and it will not be long before they are joined by biosimilar drugs. Some patients treated with selective TNF drugs may develop adverse events such as infections, malignancies, acute infusion and injection reactions, autoimmunity and cardiovascular effects. Registry data consistently show that, particularly during the first 6 months, anti-TNF drugs slightly increase the risk of serious infections of the skin, soft tissues and joints, but it does not seem to increase the risk of cancer other than nonmelanoma skin cancers. A number of studies have shown that the administration of biological agents can lead to the formation of neutralizing and nonneutralizing antibodies. Lipid levels increase, but the atherogenic index remains stable and qualitative changes to lipid particles may reduce the risk of cardiovascular diseases. Patients treated with anti-TNF drugs therefore need to be monitored regularly.

1 June 2011 in The Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
FAFabiola Atzeni
Fabiola Atzeni
Piercarlo Sarzi-PuttiniPiercarlo Sarzi-Puttini
Piercarlo Sarzi-Puttini
SSSimona Sitia
Simona Sitia
LTLivio Tomasoni
Livio Tomasoni
Luigi GianturcoLuigi Gianturco
Luigi Gianturco
MTMaurizio Turiel
Maurizio Turiel
Objective. To identify the presence of subclinical atherosclerosis in patients with psoriatic arthritis (PsA) and healthy controls using intima-media thickness (IMT), coronary flow reserve (CFR), and the plasma concentration of asymmetric dimethylarginine (ADMA), to evaluate the correlations among ADMA, IMT, and CFR. Methods. The study involved 22 patients who fulfilled the ClASsification of Psoriatic ARthritis study group criteria for PsA and a cohort of 35 healthy controls with no history or current signs of coronary artery disease (CAD). Common carotid IMT was measured using high-resolution B-mode ultrasonography. Dipyridamole transthoracic stress echocardiography was used to evaluate CFR. Blood samples were obtained to assess ADMA levels. The clinical manifestations were recorded. All patients were treated with disease-modifying antirheumatic drug, but none had received any biological or steroid therapy. Results. Plasma ADMA levels were significantly higher in the patients with PsA (0.71 ± 0.07 μmol/l vs 0.48 ± 0.07 μmol/l; p = 0.00) and CFR was significantly reduced in that group (2.86 ± 0.70 vs 3.3 ± 0.43; p < 0.01) compared to controls. Common carotid IMT was greater in the patients with PsA, but the difference was not significant (0.64 ± 0.26 mm vs 0.62 ± 0.5 mm; p = 0.65). There was a significant correlation between CFR and plasma ADMA levels in the PsA group (R = 0.28; p < 0.01), but no correlation between plasma ADMA levels and IMT (R = 0.02; p = 0.32), Disease Activity Score 28 (p = 0.52), or Psoriasis Area and Severity Index (p = 0.98). Conclusion. Our patients with PsA showed a profile of subclinical atherosclerosis. ADMA may be a useful marker of endothelial dysfunction in PsA.

16 August 2012 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
MTMaurizio Turiel
Maurizio Turiel
Luigi GianturcoLuigi Gianturco
Luigi Gianturco
Cristian RicciCristian Ricci
Cristian Ricci
Piercarlo Sarzi-PuttiniPiercarlo Sarzi-Puttini
Piercarlo Sarzi-Puttini
LTLivio Tomasoni
Livio Tomasoni
FAFabiola Atzeni
Fabiola Atzeni
Objective: An association between systemic autoimmune diseases and atherosclerosis has been described in many connective tissue diseases, and this association is known to lead to increased cardiovascular morbidity and mortality. Systemic sclerosis (SSc) is characterized by multisystem organ inflammation, endothelial wall damage, and vasculopathy. There are many markers of endothelial dysfunction and/or atherosclerotic risk, such as asymmetric dimethylarginine (ADMA), arterial stiffness parameters, carotid intima‐media thickness (CIMT), and coronary flow reserve (CFR) assessed by transthoracic echocardiography. The aim of this pilot study was to use various endothelial and atherosclerosis markers to identify early cardiovascular involvement in a group of SSc patients.Methods: The study involved 20 patients (2 men and 18 women with a mean ± SD age of 52.96 ± 12.51 years) with diffuse SSc who had no signs or symptoms of cardiovascular disease (CVD) and 20 age‐ and sex‐matched controls. All subjects underwent a dipyridamole echocardiographic stress test that included a determination of CFR and an evaluation of CIMT, arterial stiffness, and plasma ADMA levels.Results: All of the arterial wall measurements of the patients with diffuse SSc were significantly different from those of the controls, and both right and left CIMT, pulse wave velocity, and stiffness index (β) were significantly elevated in the SSc patients compared to the healthy controls. Moreover, in patients with diffuse SSc, CFR was significantly lower (P = 0.0033) and plasma ADMA levels were higher (P < 0.0001) than in healthy controls.Conclusion: SSc patients without any clinical evidence of CVD seem to have had subclinical atherosclerosis, which was suggested by early impairment of coronary microcirculation and macrovascular involvement.

1 April 2010 in Autoimmunity Reviews
Verified
Journal Article
Closed access
MTMaurizio Turiel
Maurizio Turiel
SSSimona Sitia
Simona Sitia
FAFabiola Atzeni
Fabiola Atzeni
LTLivio Tomasoni
Livio Tomasoni
Luigi GianturcoLuigi Gianturco
Luigi Gianturco
Piercarlo Sarzi-PuttiniPiercarlo Sarzi-Puttini
Piercarlo Sarzi-Puttini

3 April 2015 in Atherosclerosis
Verified
Journal Article
Closed access
PDF file
Luigi GianturcoLuigi Gianturco
Luigi Gianturco
BBB.D. Bodini
B.D. Bodini
FAF. Atzeni
F. Atzeni
CCC. Colombo
C. Colombo
DSD. Stella
D. Stella
MTM. Turiel
M. Turiel